Canaccord Genuity Maintains Buy on Progyny, Raises Price Target to $36

Benzinga Newsdesk www.benzinga.com Positive 66.7%

Neg 0% Neu 0% Pos 66.7%

Canaccord Genuity analyst Richard Close maintains Progyny (NASDAQ:PGNY) with a Buy and raises the price target from $30 to $36.